Inhaled Corticosteroids and Risk of Cardiovascular Disease in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Regression.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
Krish Gadhvi, Minnah Kandeil, Dinushan Raveendran, Jeewoo Choi, Nia Davies, Anya Nanchahal, Oliva Wing, Jennifer Quint, Hannah Whittaker
{"title":"Inhaled Corticosteroids and Risk of Cardiovascular Disease in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Regression.","authors":"Krish Gadhvi,&nbsp;Minnah Kandeil,&nbsp;Dinushan Raveendran,&nbsp;Jeewoo Choi,&nbsp;Nia Davies,&nbsp;Anya Nanchahal,&nbsp;Oliva Wing,&nbsp;Jennifer Quint,&nbsp;Hannah Whittaker","doi":"10.15326/jcopdf.2022.0386","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Previous studies have reported mixed associations between inhaled corticosteroids (ICSs) and cardiovascular disease (CVD) in people with chronic obstructive pulmonary disease (COPD). Using updated literature, we investigated the association between ICS-containing medications and CVD in COPD patients, stratified by study-related factors.</p><p><strong>Methods: </strong>We searched MEDLINE and EMBASE for studies that reported effect estimates for the association between ICS-containing medications and the risk of CVD in COPD patients. CVD outcomes specifically included heart failure, myocardial infarction, and stroke-related events. We conducted a random-effects meta-analysis and a meta-regression to identify effect-modifying study-related factors.</p><p><strong>Results: </strong>Fifteen studies met inclusion criteria and investigated the association between ICS-containing medications and the risk of CVD. Pooled results from our meta-analysis showed a significant association between ICS-containing medication and reduced risk of CVD (hazard ratio 0.87, 95% confidence intervals 0.78 to 0.97). Study follow-up time, non-ICS comparator, and exclusion of patients with previous CVD modified the association between ICS use and risk of CVD.</p><p><strong>Conclusions: </strong>Overall, we found an association between ICS-containing medications and reduced risk of CVD in COPD patients. Results from the meta-regression suggest that subgroups of COPD patients may benefit from ICS use more than others and further work is needed to determine this.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484493/pdf/JCOPDF-10-317.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15326/jcopdf.2022.0386","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Previous studies have reported mixed associations between inhaled corticosteroids (ICSs) and cardiovascular disease (CVD) in people with chronic obstructive pulmonary disease (COPD). Using updated literature, we investigated the association between ICS-containing medications and CVD in COPD patients, stratified by study-related factors.

Methods: We searched MEDLINE and EMBASE for studies that reported effect estimates for the association between ICS-containing medications and the risk of CVD in COPD patients. CVD outcomes specifically included heart failure, myocardial infarction, and stroke-related events. We conducted a random-effects meta-analysis and a meta-regression to identify effect-modifying study-related factors.

Results: Fifteen studies met inclusion criteria and investigated the association between ICS-containing medications and the risk of CVD. Pooled results from our meta-analysis showed a significant association between ICS-containing medication and reduced risk of CVD (hazard ratio 0.87, 95% confidence intervals 0.78 to 0.97). Study follow-up time, non-ICS comparator, and exclusion of patients with previous CVD modified the association between ICS use and risk of CVD.

Conclusions: Overall, we found an association between ICS-containing medications and reduced risk of CVD in COPD patients. Results from the meta-regression suggest that subgroups of COPD patients may benefit from ICS use more than others and further work is needed to determine this.

慢性阻塞性肺疾病患者吸入皮质类固醇与心血管疾病的风险:系统回顾和meta回归
背景:先前的研究报道了慢性阻塞性肺疾病(COPD)患者吸入皮质类固醇(ICSs)与心血管疾病(CVD)之间的混合关联。使用最新的文献,我们调查了含ics的药物与COPD患者CVD之间的关系,并按研究相关因素进行了分层。方法:我们在MEDLINE和EMBASE中检索了报告了含ics药物与COPD患者心血管疾病风险之间关联的效应估计的研究。CVD结果包括心力衰竭、心肌梗死和卒中相关事件。我们进行了随机效应荟萃分析和荟萃回归来确定影响研究的相关因素。结果:15项研究符合纳入标准,并调查了含ics的药物与CVD风险之间的关系。我们荟萃分析的汇总结果显示,含有ics的药物与降低心血管疾病风险之间存在显著关联(风险比0.87,95%置信区间0.78 ~ 0.97)。研究随访时间、非ICS比较物和排除既往CVD患者改变了ICS使用与CVD风险之间的关系。结论:总体而言,我们发现含ics的药物与COPD患者CVD风险降低之间存在关联。meta回归的结果表明,COPD患者亚组可能比其他亚组更受益于ICS,需要进一步的工作来确定这一点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信